Ite A. Laird‐Offringa

This study shows that immunizing SCLC mice with isoaspartylated Elavl4 after chemotherapy improves survival, mirroring the benefit seen in patients with anti-ELAVL4 antibodies.

The paper identifies TRIP13 as a mediator of AT2 cell dysfunction in IPF through integrated transcriptomic and epigenomic analysis and shows TRIP13 inhibition prevents mesenchymal gene signature acquisition.

This study identifies key epigenetic states and transcription factor networks in human alveolar epithelial differentiation, revealing dynamic enhancer changes and regulatory interactions critical for distal lung identity.